United States

Profile: Evotec AG (EVTG.DE)

EVTG.DE on Xetra

14 Dec 2018
Change (% chg)

€-0.12 (-0.62%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.

Company Address

Evotec AG

Essener Bogen 7
HAMBURG     22419
P: +4940.560810
F: +4940.56081222

Company Web Links